This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 04 April 2025; doi:10.1038/s41569-025-01146-x Hearttransplantation remains the optimal long-term treatment for appropriate patients with advanced heartfailure. However, the donor heart shortage is a limiting factor, and the risk profile of transplant candidates is worsening.
IntroductionThe objective of this study was to examine the impact of ventricular assist device support as a bridge to hearttransplantation in children with end-stage heartfailure. Patients were divided into two groups: with pre transplant ventricular assist device (VAD) support and without VAD support.
Advanced heartfailure (AdvHF) can only be treated definitively by hearttransplantation (HTx), yet problems such right ventricle dysfunction (RVD), rejection, cardiac allograft vasculopathy (CAV), and primary graft dysfunction (PGD) are linked to a poor prognosis.
The increasing prevalence of heartfailure (HF) has led to advancements in therapeutic strategies, including the development of new pharmacological treatments and the expansion of guideline recommendations across the spectrum of left ventricular ejection fractions.
RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heartfailure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/hearttransplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Atlanta, GA.
The risk of early heartfailure after hearttransplantation is lower if the donor heart is stored in a so-called heart-in-a-box instead of in the usual cooler with ice. This is according to a study by researchers at the University of Gothenburg.
However, information on its efficacy and safety in patients with heartfailure remains limited. Case presentation A 43-year-old man with a body mass index of 41 kg/m 2 was admitted to our hospital for acute heartfailure due to dilated cardiomyopathy. No adverse events were observed during B-SES.
Despite being a hearttransplantation candidate, she declined revascularization and sought alternative treatments for angina, dyspnea, and daily activity limitations. EECP may alleviate the need for hearttransplantation through its integration as a standard early intervention.
Early identification of kidney dysfunction in patients with advanced heartfailure is crucial for timely interventions. Circulation, Ahead of Print. Hemodynamic derangements and maladaptive neurohormonal upregulations contribute to fluctuations in kidney indices and electrolytes that may recover with guideline-directed medical therapy.
The risk of early heartfailure after hearttransplantation is lower if the donor heart is stored in a so-called heart-in-a-box instead of in the usual cooler with ice.
Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in hearttransplantation, heartfailure, and other complex cardiac conditions. An expert in diagnosing heartfailure, Kobashigawa also is director of the Advanced Heart Disease Division in the Smidt Heart Institute.
After struggling with heartfailure for the first months of his life, doctors told his parents that Zeke would need a hearttransplant immediately. Within one day, our hearttransplant team performed the transplant surgery. Now Zane, 6, and Zeke, 5, are living lives the odds said were unlikely.
Introduction Hearttransplantation (HT) is the only treatment option in children with heartfailure secondary to cardiomyopathies and non-reparable congenital heart diseases.
Circulation: HeartFailure, Ahead of Print. Heartfailure is a global disease with significant morbidity. Hearttransplant (HT) can be a lifesaving therapy for select patients with end-stage heartfailure.
Eosinophilic myocarditis (EM), a rare condition, is fatal if left untreated and has rarely been described in hearttransplant recipients. The cornerstone of treatment is corticosteroids, comprehensive therapy and heartfailure management (including advanced mechanical support for fulminant myocarditis).
The implantation of left ventricular assist devices (LVADs) has been increasing, with good long-term results, in parallel with a growing population with advanced heartfailure (HF). However, in some European countries, LVADs are still underused, with one of the main issues being the patient's late referral.
Getty Images milla1cf Wed, 02/21/2024 - 19:10 February 21, 2024 — Ochsner Children's Hospital , ranked among the top hospitals in the nation for pediatric cardiology and congenital heart surgery, is raising awareness of the need for more pediatric-specific heart devices. Yet, research and innovation in this field has not kept pace.
Arrhythmias can lead to cardiac arrest (CA) and heartfailure. When intractable, hearttransplant (HTX) can become the only viable treatment. This rare, high-risk cohort has not been reported as a distinct group.
Fulminant myocarditis has been defined as the clinical manifestation of cardiac inflammation with rapid-onset heartfailure and cardiogenic shock. We report on the case of a 17-year-old boy with hemodynamic de.
Pediatric hearttransplantation has long been hailed as a life-saving intervention for children suffering from end-stage heartfailure. While the procedure offers hope, the long-term outcomes for these young patients remain suboptimal due to allograft rejection and graft failure.
However, advanced heartfailure therapy never means it can be achieved only by state-of-the-art technology. Cardiac failure management remains basically disciplined medical management and a holistic approach to improve the quality of life. Only few lucky patients end up getting hearttransplantation, the ultimate treatment.
(MedPage Today) -- To more fairly rank candidates for hearttransplant, researchers developed the U.S. candidate risk score (US-CRS) and found it to better discriminate risk for people with advanced heartfailure than the current six-status system.
Pictured Left to Right: Members and students of the McGill Gene Editing Laboratory at The Texas Heart Institute in Houston, Texas: Fansen Meng, PhD, Xiao Li, PhD, James Martin, MD, PhD, Rich Li, PhD (back), Maggie Lim (undergraduate student at Rice University front), Yuka Morikawa, PhD, Ann Bromley.
Heartfailure is a chronic condition that occurs when the heart can no longer operate efficiently on its own, or effectively pump blood throughout the body. Signs of heartfailure may include difficulty breathing, a racing heartbeat/heart palpitations, fatigue, or unexplained swelling.
Objective The role of hyperuricaemia as a prognostic maker has been established in chronic heartfailure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available. Conclusions Elevated UA is associated with greater haemodynamic impairment in advanced HF.
Knowledge and application of European Society of Cardiology/HeartFailure Association (ESC/HFA) guidelines in the management of advanced heartfailure (HF). Respondents were categorized into heartfailure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs). of HFCs, 19.6%
Abstract Aims There is uncertainty about the definition of iron deficiency (ID) and the association between ID and prognosis in patients with advanced heartfailure. We evaluated three definitions of ID in patients referred for hearttransplantation. The same association was not seen with guideline definition of ID.
Introduction:Pediatric hearttransplant (PHT) recipient survival has improved. Yet, neurologic morbidity related to heartfailure and its treatment persist. Stroke, Volume 56, Issue Suppl_1 , Page ATP261-ATP261, February 1, 2025.
When a patient with heartfailure has received a new heart and survives—the transplantation is deemed a success. However, health care overlooks heart recipients who suffer from long-term and often severe symptoms, such as pain and fatigue.
Background:Many cardiovascular disorders propel the development of advanced heartfailure that necessitates cardiac transplantation. Circulation: Genomic and Precision Medicine, Volume 16, Issue 5 , Page 452-461, October 1, 2023.
Circulation: HeartFailure, Ahead of Print. Centers performing at least 1 hearttransplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.
Hearttransplant rates were low but increased slightly in 2020 for patients without CHD, with DV and SV CHD patients showing fluctuating rates peaking in 2018 and 2019, then declining in 2020. Cardiogenic shock rates were highest among SV-CHD patients, with significant fluctuations, followed by DV-CHD patients.
Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or hearttransplantation (HTx) in patients with end-stage heartfailure (HF).
This institute is dedicated to pioneering research, innovation, and the development of clinically effective techniques for addressing various heart conditions. Additionally, it offers comprehensive cardiac screening and preventive care.
Johnson & Johnson expanded deeper into heartfailure and interventional cardiology, acquiring interatrial shunt-maker V-Wave for $600M upfront and up to $1.7B These improvements would allow the Ventura IAS to address the notable HFrEF treatment gap between GDMT and far more invasive therapies like LVAD and hearttransplantation.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Cardiac allograft vasculopathy (CAV) is the leading cause of late graft dysfunction in hearttransplantation.
Circulation: HeartFailure, Ahead of Print. BACKGROUND:Right ventricular dysfunction (RVD) is common in patients with heartfailure with reduced ejection fraction, and it is associated with poor prognosis.
The association between a lower rate of MAE and EMB persisted in the multivariate model when those with hearttransplant who had EMB were compared to those without hearttransplant who did not have EMB p=0.001. The leading cause of mortality was heartfailure in 51% of deceased patients.
Hearttransplantation remains a vital treatment for end-stage heartfailure, yet the scarcity of suitable donor hearts makes the treatment unavailable to many patients in critical need. Addressing this critical barrier could potentially improve post-transplant outcomes and make older donor hearts a viable option.
Abstract Aim Cardiac resynchronization therapy (CRT) is a cornerstone in the management of chronic heartfailure in patients with a broad or paced QRS. The primary composite endpoint included all-cause mortality, hearttransplantation, or ventricular assist device implantation. ml/min/1.73 m ml/min/1.73 m
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content